{
  "ticker": "JNJ",
  "target_date": "2025-02-21",
  "actual_date": "2025-02-21",
  "collected_at": "2025-12-08T11:26:08.628528",
  "price": {
    "open": 156.37,
    "high": 159.92,
    "low": 155.79,
    "close": 158.74000549316406,
    "volume": 12546900,
    "change_1d_pct": 1.64,
    "change_7d_pct": 4.78,
    "change_30d_pct": 11.88
  },
  "technicals": {
    "rsi_14": 79.99,
    "sma_20": 150.0,
    "sma_50": 144.66,
    "macd": 3.138,
    "macd_signal": 2.389,
    "macd_histogram": 0.749,
    "bb_upper": 157.34,
    "bb_lower": 142.67,
    "price_vs_sma20_pct": 5.82,
    "price_vs_sma50_pct": 9.73,
    "volume_ratio": 1.43
  },
  "fundamentals": {
    "market_cap": 488906227712,
    "pe_ratio": 19.587357,
    "forward_pe": 19.143867,
    "price_to_book": 6.159135,
    "price_to_sales": 5.3056054,
    "profit_margin": 27.26,
    "operating_margin": 30.2,
    "roe": 33.62,
    "roa": 8.26,
    "revenue_growth": 6.8,
    "earnings_growth": 91.0,
    "debt_to_equity": 57.766,
    "current_ratio": 1.074,
    "quick_ratio": 0.711,
    "dividend_yield": 258.0,
    "fifty_two_week_high": 207.81,
    "fifty_two_week_low": 140.68,
    "fifty_day_avg": 193.4922,
    "two_hundred_day_avg": 170.2741,
    "analyst_target": 203.41833,
    "analyst_recommendation": "buy",
    "num_analysts": 24,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -2.35,
    "pct_from_52w_low": 44.25
  },
  "macro": {
    "spy": {
      "price": 594.73,
      "change_1d_pct": -1.71,
      "change_7d_pct": -0.57
    },
    "vix": {
      "level": 18.21,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.42
    },
    "dollar_index": {
      "level": 106.61
    },
    "gold": {
      "price": 2937.6
    },
    "regime": "BEAR_NORMAL"
  },
  "news": [
    {
      "headline": "Johnson & Johnson (JNJ) Up 8.9% Since Last Earnings Report: Can It Continue?",
      "source": "Yahoo",
      "datetime": 1740155425,
      "summary": "Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
      "url": "https://finnhub.io/api/news?id=6f5c41fdcc4add6733bf59447b87fd0692382272073af095b9074d622f6a6fe1"
    },
    {
      "headline": "American Century Value Fund Q4 2024 Commentary",
      "source": "SeekingAlpha",
      "datetime": 1740150660,
      "summary": "U.S. equities broadly advanced during the quarter, despite a pullback in December. Read more here.",
      "url": "https://finnhub.io/api/news?id=756196ec206fb09c24a05cc1b0af5659728fe6ed931e438d4e57b12c8390790e"
    },
    {
      "headline": "Is Johnson & Johnson (JNJ) the Best Non-Tech Stock to Buy Now for Long Term?",
      "source": "Yahoo",
      "datetime": 1740142363,
      "summary": "We recently compiled a list of the 10 Best Non-Tech Stocks to Buy Now for Long Term. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against the other non-tech stocks. Investing in non-technology stocks offers a range of benefits that can enhance an investor",
      "url": "https://finnhub.io/api/news?id=85cc871f784b07b5e7138bc02e9644058919889c5e00a646ceac46070d4c010d"
    },
    {
      "headline": "TREMFYA\u00ae (guselkumab) subcutaneous (SC) induction data support potential to be the first and only in its class to offer the option of both intravenous and SC induction therapy in ulcerative colitis",
      "source": "Finnhub",
      "datetime": 1740121267,
      "summary": "Phase 3 ASTRO study achieves primary and all secondary endpoints at Week 12 in ulcerative colitis patientsThe only SC induction data for an IL-23 inhibitor show statistically significant and...",
      "url": "https://finnhub.io/api/news?id=30c1225a81461a62abf6dcba74548bc5fc822bd070a7b047b127c76f0238eb01"
    },
    {
      "headline": "Allspring Growth Fund Q4 2024 Commentary",
      "source": "SeekingAlpha",
      "datetime": 1740116700,
      "summary": "The Allspring Growth Fund underperformed the Russell 3000 Growth Index during the quarter that ended December 31, 2024. Click here to read the full commentary. ",
      "url": "https://finnhub.io/api/news?id=ae5da5525ce79842b6b62f9e241de2b6e22aca640fbefe60c112d5b625075b6a"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "8-K",
      "date": "2025-02-20",
      "description": "d866332d8k.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000119312525030851/d866332d8k.htm"
    },
    {
      "form": "4",
      "date": "2025-02-19",
      "description": "xslF345X05/wk-form4_1740005083.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000084/xslF345X05/wk-form4_1740005083.xml"
    },
    {
      "form": "4",
      "date": "2025-02-19",
      "description": "xslF345X05/wk-form4_1740004664.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000082/xslF345X05/wk-form4_1740004664.xml"
    },
    {
      "form": "4",
      "date": "2025-02-19",
      "description": "xslF345X05/wk-form4_1740004513.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000080/xslF345X05/wk-form4_1740004513.xml"
    },
    {
      "form": "4",
      "date": "2025-02-19",
      "description": "xslF345X05/wk-form4_1740004392.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000078/xslF345X05/wk-form4_1740004392.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}